Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Our Products
MouseAtlas
iPSC Cell Lines
Knockout Cell Lines
Tumor Cell Lines
Adeno-associated Virus (AAV) Standard Capsid
Featured Catalog
Humanized Mouse Models
HUGO-GT™
HUGO-Ab™
Humanized Target Gene Models
Humanized Immune System Mouse Models
Tool Mice
Cre Mouse Lines
Disease Models
Autoimmune Disease Models
Ophthalmic Disease Models
Immunodeficient Mouse Models
Metabolic Disease Models
Neurological Disease Models
Oncology & Immuno-oncology Models
Services
Model Generation Techniques
Turboknockoutᵀᴹ Gene Targeting
Cre-ESCs Gene Editing
Targeted Gene Editing
Genetically Engineered Animals
Knockin Mice
Knockin Rats
Knockout Mice
Knockout Rats
Transgenic Mice
Transgenic Rats
Transgenic Model Generation
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Adenovirus Packaging
Lentivirus Packaging
Custom Cell Line Services
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Overexpression Cell Lines
Point Mutation Cell Lines
Breeding & Supporting Services
BAC Modification
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
Drug Discovery and Development
Antibody Discovery Platform
HUGO-Ab™
HUGO-Mab™
HUGO-Light™
HUGO-Nano™
HUGO-Ab-eKO™
Therapeutic Area
Neurology
Alzheimer's Disease (AD)
Parkinson's Disease (PD)
Huntington's Disease (HD)
Blood Brain Barrier (BBB)
Metabolic & Cardiovascular
Obesity
Ophthalmology
Glaucoma
Age-Related Macular Degeneration (AMD)
Oncology
PBMC Humanized Mouse Model
Human Immune System (HIS) Mouse Model
Immunology & Inflammation
Asthma
Innovative Drug R&D
Therapeutic Antibody Drugs
Monoclonal Antibodies (mAb)
Bispecific Antibodies (BsAb)
ADC/AOC
AI-Powered AAV Discovery
Cell Immunotherapy
Gene Therapy
Oligonucleotide Therapy
Fully Human Antibody Library
Neurology Antibodies
Metabolic & Cardiovascular Antibodies
Ophthalmology Antibodies
Oncology Antibodies
Immunology & Inflammation Antibodies
Resources
News
Blogs & Insight
Promotion
Events & Webinars
Databases
AbSeek
Rare Disease Data Center
Cell iGeneEditor™ System
Citations
Resource Vault
OriCell
About Us
Animal Health & Welfare
Corporate Overview
Facility Overview
Our Team
Our Partners
Careers
Health Reports
Contact Us
Login

Disruption Of LARP7-Mediated U6 snRNA Modification Links Aberrant Splicing To Infertility And Alazami Syndrome

Cyagen Technical Content Team | September 06, 2025
Larp7-KO Mice: Modeling Alazami Syndrome & Infertility
Study U6 snRNA modification and splicing fidelity with Cyagen's validated Larp7-KO models.
Larp7-KO Mice: Modeling Alazami Syndrome & Infertility
Contents
01. The Role of U6 snRNA and its Modifications in mRNA Splicing 02. Testicular Tissue: An Ideal Model for Studying RNA Splicing and U6 Modification 03. LARP7-Mediated U6 Modification: Ensuring Splicing Fidelity and Spermatogenesis 04. Human Insights: LARP7 Mutations, U6 Modification, and Alazami Syndrome 05. Conclusion: Impact on Splicing Mechanisms and Disease Diagnosis 06. References

The Role of U6 snRNA and its Modifications in mRNA Splicing

In higher eukaryotes, most genes contain introns. After transcription is complete, the removal of introns from mRNA should be done by splicing to generate mature and translationally active mRNA. This process is carried out and stimulated by the spliceosome. The main spliceosome contains five types of snRNA (small nuclear RNA), i.e., U1, U2, U4, U5, and U6, as well as the protein factors that interact with them [1]. Among them, U6 snRNA is at the core and most conservative position. It is located at the catalytic center of the spliceosome, which is essential for the catalytic activity of the spliceosome [2]. At the same time, it was also found that U6 is highly modified in metamorphosis, including the modifications taking place in the 5’ terminal γ-monomethylation capping and 3-oligomeric uridine, as well as the intermediate 2-O-methylated, pseudouridine, m2G and m6A, etc. [3,4]. After nearly 40 years of research, researchers have revealed the biological production process of U6 and its functional mechanism in splicing, but the regulatory mechanism of U6 modification and its function in mRNA splicing is still not well understood.

Testicular Tissue: An Ideal Model for Studying RNA Splicing and U6 Modification

Previous studies have found that in adult mammals, the testis has the tissue with the highest transcriptional activity and the most abundant alternative splicing [5], which implies that the RNA splicing machinery of the testes may be highly active. Consistent with this, spermatogenesis is regulated by specific spatiotemporal expression of genes - each stage of spermatogenic cell development has a specific gene regulation and alternative splicing of genes related to signal transduction. Therefore, the testicular tissues should be an ideal system for studying mammalian U6 modification and its effect on mRNA splicing.

LARP7-Mediated U6 Modification: Ensuring Splicing Fidelity and Spermatogenesis

On February 3rd, 2020, Mo-Fang Liu’s research team, affiliated with the Center for Excellence in Molecular Cell Science, CAS, published an article titled “LARP7-Mediated U6 snRNA Modification Ensures Splicing Fidelity and Spermatogenesis in Mice” in Molecular Cell. The publication reports that RNA-binding protein LARP7 mediates the 2-O-methylation modification of U6 by promoting the interaction between U6 snRNA and the box C/D snoRNP with catalytic activity for RNA methylation - further proving that this process is essential for mRNA splicing fidelity and spermatogenesis in the spermatogenic cells of mice.

LARP7 mediates U6 2-O-methylation modification, essential for mRNA splicing fidelity.

In this study, the members of Mo-Fang Liu’s research team used mouse testes as a model system to explore the regulatory mechanism of U6 snRNA modification and its function in mRNA splicing. They found that the LARP7 protein, which is highly expressed in the testes, is essential for the 2-O-methylation modification of U6 in spermatogenic cells. It has been found that RNA-binding protein LARP7 inhibits the elongation of RNA polymerase II transcription by binding to 7SK RNA [6,7]. Some studies show that Larp7 gene mutation is associated with human Alazami syndrome [8]. Further mechanism research reveals that LARP7 binds to U6 and snoRNA simultaneously to assist U6 loading onto box C/D snoRNP, thus promoting the methyltransferase FBL in box C/D snoRNP to achieve 2-O-methylation modification of it. More importantly, they found that LARP7-mediated U6 2-O-methylation modification is vital for precise mRNA splicing and spermatogenesis in mouse spermatogenic cells.

Human Insights: LARP7 Mutations, U6 Modification, and Alazami Syndrome

The animal experiments indicate that specifically knocking out the Larp7 gene in the germ cells causes infertility in male mice (the Larp7 gene conditional knockout mice came from Cyagen Biosciences).

This study revealed the regulatory mechanism of U6 snRNA modification and proved for the first time that U6 2-O-methylation modification is essential for precise splicing of mammalian mRNA and spermatogenesis in mouse spermatogenic cells.

In addition, both Gunter Meister’s research team, from the University of Regensburg, Germany, and Utz Fischer’s research team, from the University of Würzburg, also partnered with Mo-Fang Liu’s research team to publish an article titled “The Alazami Syndrome-associated Protein LARP7 Guides U6 small nuclear RNA Modification and Contributes to Splicing Robustness”. This article reports that the LARP7 in human cells can also mediate the 2-O-methylation modification of U6 by binding U6 and snoRNA. More importantly, in a patient with Alazami syndrome carrying a Larp7 mutation, they detected reduced 2-O-methylation modification of U6 and abnormal mRNA splicing.

Conclusion: Impact on Splicing Mechanisms and Disease Diagnosis

Together, these research works prove that LARP7 mediates U6 modification and affects precise mRNA splicing in mammals. Their findings not only reveal the regulatory mechanism of U6 modification and its effect on mRNA splicing, but also help to analyze the pathogenesis of male infertility, Alazami syndrome, etc., and provide a theoretical basis and method for the diagnosis and treatment of related diseases.

References

1. Patel, A.A., and Steitz, J.A. (2003). Splicing double: insights from the second spliceosome. Nat Rev Mol Cell Bio 4, 960-970.

2. Didychuk, A.L., Butcher, S.E., and Brow, D.A. (2018). The life of U6 small nuclear RNA, from cradle to grave. RNA 24, 437-460.

3. Epstein, P., Reddy, R., Henning, D., and Busch, H. (1980). The nucleotide sequence of nuclear U6 (4.7 S) RNA. J Biol Chem 255, 8901-8906.

4. Harada, F., Kato, N., and Nishimura, S. (1980). The nucleotide sequence of nuclear 4.8S RNA of mouse cells. Biochem Biophys Res Commun 95, 1332-1340.

5. White-Cooper, H., and Davidson, I. (2011). Unique aspects of transcription regulation in male germ cells. Cold Spring Harb Perspect Biol 3 a002626.

6. Krueger, B.J., Jeronimo, C., Roy, B.B., Bouchard, A., Barrandon, C., Byers, S.A., Searcey, C.E., Cooper, J.J., Bensaude, O., and Cohen, E.A., et al. (2008). LARP7 is a stable component of the 7SK snRNP while P-TEFb, HEXIM1 and hnRNP A1 are reversibly associated. Nucleic Acids Res 36, 2219-2229.

7. Markert, A., Grimm, M., Martinez, J., Wiesner, J., Meyerhans, A., Meyuhas, O., Sickmann, A., and Fischer, U. (2008). The La-related protein LARP7 is a component of the 7SK ribonucleoprotein and affects transcription of cellular and viral polymerase II genes. EMBO Rep 9, 569-575.

8. Alazami, A.M., Al-Owain, M., Alzahrani, F., Shuaib, T., Al-Shamrani, H., Al-Falki, Y.H., Al-Qahtani, S.M., Alsheddi, T., Colak, D., and Alkuraya, F.S. (2012). Loss of function mutation in LARP7, chaperone of 7SK ncRNA, causes a syndrome of facial dysmorphism, intellectual disability, and primordial dwarfism. Hum Mutat 33, 1429-1434.

Subscribe to Receive Updates & Promotions From Cyagen
Subscribe
* Your privacy matters to us. We never share it with third parties.
Explore More
Science (IF=47.3): PIEZO1-Driven Liver Regeneration Research Supported by Cyagen Mouse Models
Accelerating Alzheimer's Research Using Advanced iPSC Platforms
MND Awareness Day 2026: Overcoming ALS Drug Development Bottlenecks with Predictive In Vivo Tools
The PROTAC Era: From VEPPANU’s Landmark Approval to the Next Generation of CRBN-Targeted Therapies
Share
Top
Ready to Elevate Your Research?
Discover how Cyagen can support your research. Let’s start a conversation.
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0336
Email:
inquiry@cyagen.com
Services
HUGO-GT™HUGO-Ab™iPSC Cell LinesAdeno-associated Virus (AAV) Standard Capsid
Drug R&D
NeurologyMetabolicOphthalmologyOncology
About Us
Animal Health & WelfareCorporate OverviewOur TeamHealth Reports
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Global Antibody Drug Industry Development BlueBook (Frost & Sullivan)
Key Insights
The industry is undergoing a rapid transformation driven by next-generation modalities, globalized markets, and upstream technological innovations.
  • Market Structural Shift: Monoclonal antibodies drive steady growth, but ADCs and bispecifics are rapidly accelerating, reshaping the market with higher-value innovations.
  • Chinese Market Globalization: China is actively expanding globally, evidenced by a surge in high-value cross-border license-out deals.
  • Technology-Driven Efficiency: Advanced discovery engines—exemplified by Cyagen's HUGO-Ab platform and AI algorithms—are streamlining candidate screening, optimizing molecular design, and localizing the upstream supply chain.
  • Oncology-Focused Innovation: R&D pipelines remain heavily concentrated on high-incidence malignancies like non-small cell lung cancer, utilizing complex modalities to combat clinical resistance.
Now Available for Download
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest
Main Area of Research